51 results about "Tumour volume" patented technology

This invention relates to the destruction of pathological volumes or target structures such as cancerous tumors or aberrant functional target tissue volumes by direct thermal destruction. In the case of a tumor, the destruction is implemented in one embodiment of the invention by percutaneous insertion of one or more radiofrequency probes into the tumor and raising the temperature of the tumor volume by connection of these probes to a radiofrequency generator outside of the body so that the isotherm of tissue destruction enshrouds the tumor. The ablation isotherm may be predetermined and graded by proper choice of electrode geometry and radiofrequency (rf) power applied to the electrode with or without temperature monitoring of the ablation process. Preplanning of the rf electrode insertion can be done by imaging of the tumor by various imaging modalities and selecting the appropriate electrode tip size and temperature to satisfactorily destroy the tumor volume. Computation of the correct three-dimensional position of the electrode may be done as part of the method, and the planning and control of the process may be done using graphic displays of the imaging data and the rf ablation parameters. Specific electrode geometries with adjustable tip lengths are included in the invention to optimize the electrodes to the predetermined image tumor size.

A method for in-situ monitoring both the balloon/cavity and the radioactive source in brachytherapy treatment utilizing using at least one pair of miniature gamma cameras to acquire separate images of: 1) the radioactive source as it is moved in the tumor volume during brachytherapy; and 2) a relatively low intensity radiation source produced by either an injected radiopharmaceutical rendering cancerous tissue visible or from a radioactive solution filling a balloon surgically implanted into the cavity formed by the surgical resection of a tumor.

The invention discloses new applications f tetrahydropalmatine. The new application is an application that tetrahydropalmatine shown in formula I or salts thereof which are acceptable in pharmacy are used to prepare medicines used for inhibiting the proliferation of tumor cells and an application for preparing medicines used for preventing and/or curing tumors. The result of the in vivo experiment using nude mice shows that tetrahydropalmatine can effectively inhibit the growth of tumors, and the tumor volume is much smaller than the volume of the negative control group. Therefore, tetrahydropalmatine which is widely used for analgesia has good antitumor activity, and the result shows that tetrahydropalmatine can be used to prepare medicines for curing cancers, in particular to prepare medicines for curing the lung cancer. The invention broadens the medical application field of tetrahydropalmatine.

The invention discloses a tumor puncture path obtaining method, a storage medium and electronic equipment. The method comprises the following steps of: acquiring body surface data, tumor data and tissue structure data; obtaining a tumor central point according to the tumor data; selecting a needle insertion area from the body surface data according to the tumor data; obtaining a plurality of puncture paths which are not intersected with a tissue structure corresponding to the tissue structure data according to the needle insertion area and the tumor central point; and selecting a target puncture path from the plurality of puncture paths as a tumor puncture path according to the tumor volume in the tumor data, a plurality of ice ball growth durations in the tumor cryoablation operation process in each puncture path, and the volume of an ice ball, the volume of a tumor ice ball covered by the ice ball and the volume of a non-tumor ice ball covered by the ice ball in a non-tumor area corresponding to each ice ball growth duration. Therefore, selection of the tumor puncture path is more reasonable, and the situation that in the prior art, selection of the tumor puncture path is not reasonable, and consequently the operation effect is affected is effectively avoided.

The present disclosure provides methods of conducting and analyzing mouse clinical trials. In one embodiment, the method comprises the steps of receiving a dataset of tumor volumes measured in a mouse clinical trial, determining tumor growth curve of the treatment group and tumor growth curve of the control group; determining area under curve (AUC) of the treatment group and AUC of the control group; and evaluating efficacy of the drug based on an AUC ratio between the AUC of the treatment group and the AUC of the control group, wherein the mouse clinical trial comprises the steps of: obtaining a tumor sample derived from a patient; grafting the tumor sample to a treatment group comprising m mice and a control group comprising n mice, wherein m and n are integers; treating the treatment group with a drug; treating the control group with a vehicle; and measuring tumor volume of the treatment group and tumor volume of the control group at a plurality of days.

The present invention discloses a tumor immunotherapy target aiming at tumor-associated macrophages. Experiments prove that LSECtin, BTN3A2 and BNT3A3 can promote tumor progression by promoting of thestemness maintenance of tumor cells, more specifically, formation of tumor cell spheres, expression of stem transcription factors and tumor progression in a mice tumor model are promoted; by inhibition of interaction of the LSECtin with the BTN3A2 and the BTN3A3, the tumor progression can be effectively slowed down, more specifically, the incidence of tumors is reduced, and tumor volume growth can be slowed down.

Systems, methods, and computer-readable storage media providing techniques for probing in-vivo beam ranges directly using therapeutic beams for particle therapy treatment are disclosed. In an embodiment, a configuration is determined for one or more probing spots, each spot corresponding to a planned location within an interior region of a tumor volume where a dose of radiation is to be delivered. At least one therapeutic beam is provided to the tumor volume, and one or more images may be captured to provide an indication of the range/depth of the probing spots. Providing the probing spots to the interior of the tumor volume reduces the risk that the dose is provided to sensitive tissue (e.g., because even if the dose is delivered to a location other than the planned location, the dose is likely to remain contained within the tumor volume).

A method and apparatus for measuring tumors such as subcutaneous tumors is provided. A device having a flexible membrane is positioned over the tumor and displaced toward the tumor so that the tumor deforms the flexible membrane. Deforming the membrane changes the pressure or volume within a fluid-filled cavity. A gauge measures the change in volume or pressure and the gauge reading correlates with the volume of the tumor.

The invention relates to a method for preparing a human pituitary adenoma cell line, the human pituitary adenoma cell line obtained through the method, and applications of the human pituitary adenoma cell line in medicine research and development. The method comprises the following steps: (a) transplanting the human pituitary adenoma to a non-human animal suffering from immune deficiency; (b) when the weight of the transplanted pituitary adenoma achieves 15% or above of the body weight of the non-human animal or when the size of the transplanted tumor does not increase, taking out the pituitary adenoma, and transplanting the pituitary adenoma into the new non-human animal suffering from immune deficiency; (c) repeating the step (b), when the Ki67 positive expression ratio of the pituitary adenoma cells is 20% or above, taking out the pituitary adenoma; and (d) culturing the pituitary adenoma cells which are taken out, thus obtaining the pituitary adenoma cell line.

Tumor responses to a therapy can be predicted in a more objective and quantitative fashion allowing doctors to make earlier determinations of how well a tumor is responding to therapy. If a patient were not responding well, valuable time could be saved and the patient could be switched to a more efficacious therapy. Tumor response predictions to therapy are determined from a combination of (i) the tumor volumes over time, (ii) the cellular proliferation over time and (iii) the cellular apoptosis over time.

A three-dimensional tumor ruler and holder and methods of use thereof are provided. One embodiment provides a three-dimensional tumor ruler to simultaneously measure the length, width, and height of a tumor when positioned on or near the tumor. The tumor measurements can then be used to calculate tumor volume. Tumor volume can be used to accurately determine for example the dose of a drug or radiation to administer to a subject. In another embodiment, the tumor ruler can be used to position the tumor during administration of a drug or radiation therapy to maximize exposure of the tumor to the therapy.

The present invention relates to a method for monitoring a hadron bundle during hadron therapy treatment of a subject comprising tumor cells labeled with a radiopharmaceutical product wherein the hadron bundle comprises a plurality of discrete hadron bursts, the method comprising the steps of: when the bursts strike the subject, monitoring the hadron bursts in the subject; detecting (111), by a Compton telescope, instantaneous gamma rays resulting from the interaction of the outbreak hadron with the tissue of the subject, and reconstructing (112) an image of the interaction volume; extracting (121), by a Compton telescope, the locations of the tumor cells labeled with the radiopharmaceutical product when no burst impacts the subject, reconstructing (122) an image of the total tumor volume; the image of the interaction volume and the image of the total tumor volume are compared (131) in order to locate the measured interaction volume relative to the measured total tumor volume.